HYMPAVZI’s approval is based on Phase 3 study results demonstrating non-inferiority and superiority compared to routine prophylaxis in eligible patients with hemophilia A or B without inhibitors
Univar Solutions' pharmaceutical ingredients portfolio will be strengthened by the addition of a broad range of cellulose ethers and other excipient solutions
This agreement reinforces Lubrizol’s commitment to Make-In-India and broadens a previously committed US$ 350 million investment to support local manufacturing
The MoU signed in 2022 has progressed and culminated in the subsumption of FOGSI-led Manyata initiative’s 20 quality standards across NABH’s Certification programs
This includes $2 billion of new investment creating more than a thousand new, high-skilled jobs
Emraclidine was well-tolerated with an adverse event profile consistent with Phase 1b trial
We are witnessing a steady and sustainable growth in the country as the Q2 revenue from operations increased by 31%
He specializes in financial planning, audit, compliance and ERP implementation, with extensive experience in leading automation and risk management projects
ISB 2001 demonstrated a favorable safety and tolerability profile, and an overall response rate (ORR) of 75% in r/r MM
Raises 2024 revenue guidance to a range of US$ 61 to US$ 64 billion
Subscribe To Our Newsletter & Stay Updated
